138 related articles for article (PubMed ID: 23809172)
1. C-Glucosides with heteroaryl thiophene as novel sodium-dependent glucose cotransporter 2 inhibitors.
Koga Y; Sakamaki S; Hongu M; Kawanishi E; Sakamoto T; Yamamoto Y; Kimata H; Nakayama K; Kuriyama C; Matsushita Y; Ueta K; Tsuda-Tsukimoto M; Nomura S
Bioorg Med Chem; 2013 Sep; 21(17):5561-72. PubMed ID: 23809172
[TBL] [Abstract][Full Text] [Related]
2. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
Nomura S; Sakamaki S; Hongu M; Kawanishi E; Koga Y; Sakamoto T; Yamamoto Y; Ueta K; Kimata H; Nakayama K; Tsuda-Tsukimoto M
J Med Chem; 2010 Sep; 53(17):6355-60. PubMed ID: 20690635
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.
Imamura M; Nakanishi K; Suzuki T; Ikegai K; Shiraki R; Ogiyama T; Murakami T; Kurosaki E; Noda A; Kobayashi Y; Yokota M; Koide T; Kosakai K; Ohkura Y; Takeuchi M; Tomiyama H; Ohta M
Bioorg Med Chem; 2012 May; 20(10):3263-79. PubMed ID: 22507206
[TBL] [Abstract][Full Text] [Related]
4. C-Aryl glucoside SGLT2 inhibitors containing a biphenyl motif as potential anti-diabetic agents.
Ding Y; Mao L; Xu D; Xie H; Yang L; Xu H; Geng W; Gao Y; Xia C; Zhang X; Meng Q; Wu D; Zhao J; Hu W
Bioorg Med Chem Lett; 2015 Jul; 25(14):2744-8. PubMed ID: 26026363
[TBL] [Abstract][Full Text] [Related]
5. Conformationally constrained spiro C-arylglucosides as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
Lv B; Feng Y; Dong J; Xu M; Xu B; Zhang W; Sheng Z; Welihinda A; Seed B; Chen Y
ChemMedChem; 2010 Jun; 5(6):827-31. PubMed ID: 20414917
[No Abstract] [Full Text] [Related]
6. ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
Xu B; Feng Y; Lv B; Xu G; Zhang L; Du J; Peng K; Xu M; Dong J; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Seed B; Chen Y
Bioorg Med Chem; 2010 Jun; 18(12):4422-32. PubMed ID: 20576578
[TBL] [Abstract][Full Text] [Related]
7. C-aryl glucosides substituted at the 4'-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
Xu B; Feng Y; Cheng H; Song Y; Lv B; Wu Y; Wang C; Li S; Xu M; Du J; Peng K; Dong J; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Roberge JY; Seed B; Chen Y
Bioorg Med Chem Lett; 2011 Aug; 21(15):4465-70. PubMed ID: 21737266
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of novel C-aryl d-glucofuranosides as sodium-dependent glucose co-transporter 2 inhibitors.
Lin TS; Liw YW; Song JS; Hsieh TC; Yeh HW; Hsu LC; Lin CJ; Wu SH; Liang PH
Bioorg Med Chem; 2013 Nov; 21(21):6282-91. PubMed ID: 24071445
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel N-β-D-xylosylindole derivatives as sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the management of hyperglycemia in diabetes.
Yao CH; Song JS; Chen CT; Yeh TK; Hung MS; Chang CC; Liu YW; Yuan MC; Hsieh CJ; Huang CY; Wang MH; Chiu CH; Hsieh TC; Wu SH; Hsiao WC; Chu KF; Tsai CH; Chao YS; Lee JC
J Med Chem; 2011 Jan; 54(1):166-78. PubMed ID: 21128592
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of thiophene-C-glucosides as sodium-dependent glucose cotransporter 2 inhibitors.
Sakamaki S; Kawanishi E; Koga Y; Yamamoto Y; Kuriyama C; Matsushita Y; Ueta K; Nomura S
Chem Pharm Bull (Tokyo); 2013; 61(10):1037-43. PubMed ID: 24088695
[TBL] [Abstract][Full Text] [Related]
11. Novel macrocyclic C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents.
Kim MJ; Lee SH; Park SO; Kang H; Lee JS; Lee KN; Jung ME; Kim J; Lee J
Bioorg Med Chem; 2011 Sep; 19(18):5468-79. PubMed ID: 21868239
[TBL] [Abstract][Full Text] [Related]
12. N-Glucosides as human sodium-dependent glucose cotransporter 2 (hSGLT2) inhibitors.
Yamamoto Y; Kawanishi E; Koga Y; Sakamaki S; Sakamoto T; Ueta K; Matsushita Y; Kuriyama C; Tsuda-Tsukimoto M; Nomura S
Bioorg Med Chem Lett; 2013 Oct; 23(20):5641-5. PubMed ID: 23999047
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of C-glucosides with azulene rings as selective SGLT2 inhibitors for the treatment of type 2 diabetes mellitus: discovery of YM543.
Ikegai K; Imamura M; Suzuki T; Nakanishi K; Murakami T; Kurosaki E; Noda A; Kobayashi Y; Yokota M; Koide T; Kosakai K; Ohkura Y; Takeuchi M; Tomiyama H; Ohta M
Bioorg Med Chem; 2013 Jul; 21(13):3934-48. PubMed ID: 23651509
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationship studies of 4-benzyl-1H-pyrazol-3-yl β-d-glucopyranoside derivatives as potent and selective sodium glucose co-transporter 1 (SGLT1) inhibitors with therapeutic activity on postprandial hyperglycemia.
Fushimi N; Fujikura H; Shiohara H; Teranishi H; Shimizu K; Yonekubo S; Ohno K; Miyagi T; Itoh F; Shibazaki T; Tomae M; Ishikawa-Takemura Y; Nakabayashi T; Kamada N; Ozawa T; Kobayashi S; Isaji M
Bioorg Med Chem; 2012 Nov; 20(22):6598-612. PubMed ID: 23062824
[TBL] [Abstract][Full Text] [Related]
15. O-Spiro C-aryl glucosides as novel sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
Xu B; Lv B; Feng Y; Xu G; Du J; Welihinda A; Sheng Z; Seed B; Chen Y
Bioorg Med Chem Lett; 2009 Oct; 19(19):5632-5. PubMed ID: 19700318
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of novel C-indolylxylosides as sodium-dependent glucose co-transporter 2 inhibitors.
Yao CH; Song JS; Chen CT; Yeh TK; Hsieh TC; Wu SH; Huang CY; Huang YL; Wang MH; Liu YW; Tsai CH; Kumar CR; Lee JC
Eur J Med Chem; 2012 Sep; 55():32-8. PubMed ID: 22818040
[TBL] [Abstract][Full Text] [Related]
17. Novel thiophenyl C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents.
Lee SH; Song KS; Kim JY; Kang M; Lee JS; Cho SH; Park HJ; Kim J; Lee J
Bioorg Med Chem; 2011 Oct; 19(19):5813-32. PubMed ID: 21906953
[TBL] [Abstract][Full Text] [Related]
18. Indole-glucosides as novel sodium glucose co-transporter 2 (SGLT2) inhibitors. Part 2.
Zhang X; Urbanski M; Patel M; Cox GG; Zeck RE; Bian H; Conway BR; Beavers MP; Rybczynski PJ; Demarest KT
Bioorg Med Chem Lett; 2006 Mar; 16(6):1696-701. PubMed ID: 16380256
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of novel tetrahydroisoquinoline-C-aryl glucosides as SGLT2 inhibitors for the treatment of type 2 diabetes.
Pan X; Huan Y; Shen Z; Liu Z
Eur J Med Chem; 2016 May; 114():89-100. PubMed ID: 26974378
[TBL] [Abstract][Full Text] [Related]
20. Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: 1,3,4-Thiadiazolylmethylphenyl glucoside congeners.
Lee J; Lee SH; Seo HJ; Son EJ; Lee SH; Jung ME; Lee M; Han HK; Kim J; Kang J; Lee J
Bioorg Med Chem; 2010 Mar; 18(6):2178-2194. PubMed ID: 20181486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
